Holen Sie sich die Stockscreener-App
410.78
0.72%
2.93
Handel nachbörslich:
410.78
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TMO?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$407.85
Offen:
$407.07
24-Stunden-Volumen:
3.01M
Relative Volume:
1.35
Marktkapitalisierung:
$158.51B
Einnahmen:
$42.90B
Nettoeinkommen (Verlust:
$6.52B
KGV:
24.09
EPS:
17.05
Netto-Cashflow:
$6.72B
1W Leistung:
-2.17%
1M Leistung:
-2.03%
6M Leistung:
-25.55%
1J Leistung:
-28.39%
1-Tages-Spanne:
$402.81
$415.75
1-Wochen-Bereich:
$402.81
$431.44
52-Wochen-Spanne:
$402.81
$627.88
Thermo Fisher Scientific Inc Stock (TMO) Company Profile
Firmenname
Thermo Fisher Scientific Inc
Sektor
Branche
Telefon
(781) 622-1000
Adresse
168 THIRD AVENUE, WALTHAM, MA
Vergleichen Sie TMO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TMO
Thermo Fisher Scientific Inc
|
410.78 | 158.51B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
194.82 | 140.78B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
489.98 | 37.91B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
108.70 | 31.23B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
153.29 | 26.31B | 15.41B | 1.37B | 2.11B | 7.50 |
Thermo Fisher Scientific Inc Stock (TMO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-10 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2024-12-23 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-10-14 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-10-01 | Eingeleitet | Stephens | Overweight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-03-18 | Fortgesetzt | Citigroup | Neutral |
| 2024-01-24 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-01-08 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2023-12-18 | Eingeleitet | HSBC Securities | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-10-26 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-10-25 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-09-06 | Fortgesetzt | Citigroup | Buy |
| 2023-07-19 | Eingeleitet | Raymond James | Outperform |
| 2023-07-19 | Bestätigt | Robert W. Baird | Outperform |
| 2023-07-13 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2023-04-04 | Bestätigt | Barclays | Overweight |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-10-27 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-08-25 | Eingeleitet | Credit Suisse | Neutral |
| 2022-04-25 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2022-01-26 | Fortgesetzt | Barclays | Overweight |
| 2021-10-20 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-07-16 | Eingeleitet | The Benchmark Company | Buy |
| 2021-03-18 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-03 | Eingeleitet | Barclays | Overweight |
| 2021-01-08 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-02 | Eingeleitet | Goldman | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2020-09-30 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-09-14 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-08-20 | Fortgesetzt | JP Morgan | Overweight |
| 2020-07-15 | Hochstufung | Cleveland Research | Neutral → Buy |
| 2020-07-07 | Bestätigt | Needham | Buy |
| 2020-04-23 | Bestätigt | Needham | Buy |
| 2020-01-31 | Bestätigt | Needham | Buy |
| 2020-01-22 | Eingeleitet | Credit Suisse | Neutral |
| 2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-11-15 | Eingeleitet | Stifel | Buy |
| 2019-07-25 | Bestätigt | Needham | Buy |
| 2019-07-16 | Herabstufung | Needham | Strong Buy → Buy |
| 2019-05-30 | Eingeleitet | Wolfe Research | Outperform |
| 2019-05-23 | Bestätigt | Needham | Strong Buy |
| 2019-04-22 | Bestätigt | Needham | Strong Buy |
| 2019-04-16 | Bestätigt | BofA/Merrill | Buy |
Alle ansehen
Thermo Fisher Scientific Inc Aktie (TMO) Neueste Nachrichten
Digital Genome Market Forecast: Growth Trends, Key Players & - openPR.com
Neuroendocrine Tumor Treatment Market: Investment Analysis & - openPR.com
Tissue Diagnostics Market to Reach $12.4 Billion by 2029, Growing at 7.0% CAGR - GlobeNewswire Inc.
Here's How Much You Would Have Made Owning Thermo Fisher Scientific Stock In The Last 20 Years - Benzinga
Thermo Fisher Scientific Inc. (TMO): Among Billionaire Mario Gabelli’s Large-Cap Stock Picks with Huge Upside Potential - Yahoo Finance
Engineer III, Manufacturing Engineering (Waltham, MA, USA) - The Chemical Engineer Job Board
Thermo Fisher Scientific: 4 Reasons This Oversold Stock Is a Buy - Morningstar
Custom Antibody Market To Hit USD 1,230.09 Billion By 2032 | - openPR.com
High Content Screening Market Global Forecasts 2025-2030 - GlobeNewswire
Smarter protection: New Class II biological safety cabinet - Labmate Online
Thermo Fisher Scientific Inc. (TMO): Among Richard Chilton’s Stock Picks with Huge Upside Potential - Insider Monkey
Thermo Fisher Scientific to Present at BofA Securities 2025 Health Care Conference on May 13 - BioSpace
Thermo Fisher’s new biosafety cabinet offers improved lab safety and user experience - BioSpectrum Asia
Oversold Conditions For Thermo Fisher Scientific (TMO) - Nasdaq
Thermo Fisher Scientific Inc. stock falls Tuesday, underperforms market - MarketWatch
Thermo Fisher CEO Marc Casper to Share Strategic Updates at Major Healthcare Conference - Stock Titan
Benzyl Alcohol Market Scope: Growth, Share, Value, Size, - openPR.com
Global Raman Spectroscopy Market Is Booming So Rapidly - openPR.com
Immune Cell Engineering Market Generated Opportunities, - openPR.com
Laboratory Equipment Market Future Business Opportunities - openPR.com
Genome Engineering Market Generated Opportunities, Future - openPR.com
Is Thermo Fisher Scientific (TMO) One of the Best Falling Stocks to Buy According to Analysts? - Insider Monkey
Thermo Fisher Scientific to cut jobs at Orlando location - Yahoo Finance
RoosterBio Announces Collaboration with Thermo Fisher Scientific to Advance Cell & Exosome Therapy Manufacturing - PRWeb
THERMO FISHER SCIENTIFIC INC. SEC 10-Q Report - TradingView
Epigenetics Market Is Booming So Rapidly 2025-2032 -Illumina - openPR.com
Thermo Fisher Scientific Inc (TMO) Stock Analysis: A Closer Look at the 35.79% Potential Upside - DirectorsTalk Interviews
RoosterBio announces collaboration with Thermo Fisher to advance cell therapy manufacturing - BioSpectrum Asia
Thermo Fisher Scientific Leverages Integrated Solutions To Accelerate the Development of Biologic Therapeutics - Technology Networks
RoosterBio and Thermo Fisher Scientific Agree to Collaborate to Advance Cell and Exosome Therapy Manufacturing - Genetic Engineering and Biotechnology News
Lab Automation Market Set to Witness Significant Growth - openPR.com
Thermo Fisher commits $2bn to boost US operations - The Manufacturer
Thermo Fisher Scientific (NYSE:TMO) Collaborates With RoosterBio To Advance Cell Therapy Solutions - simplywall.st
Thermo Fisher reports Q1 growth, charts a steady course for 2025 - BioProcess International
Thermo Fisher Launches Improved Biological Safety Cabinet - Contract Pharma
RoosterBio Announces Collaboration with Thermo Fisher Scientific to Advance Cell and Exosome Therapy Manufacturing - PR Newswire
Research Grade Proteins Market to Witness Massive Growth by 2032 - openPR.com
Thermo Fisher Scientific employs an enhanced platform technology - European Pharmaceutical Manufacturer
Cell Lysis Market Growth in Future Scope 2025-2032 | Thermo - openPR.com
Thermo Fisher Scientific Inc. (NYSE:TMO) Q1 2025 Earnings Call Transcript - MSN
RoosterBio, Thermo Fisher Partner to Advance Cell & Exosome Therapy Manufacturing - Contract Pharma
Thermo Fisher (TMO) Target Price Reduced by Argus | TMO Stock Ne - GuruFocus
Thermo Fisher To Buy Phadia For $3.5 Billion - CHEManager Online
Argus Adjusts Price Target on Thermo Fisher Scientific to $470 From $620 - marketscreener.com
Thermo Fisher accelerates development of biologic therapeutics - BioSpectrum Asia
Thermo Fisher Scientific Leverages Integrated Solutions to Accelerate the Development of Biologic Therapeutics - BioSpace
Pharmacogenomics Market Detailed In New Research Report 2025 | - openPR.com
Thermo Fisher Scientific to invest $2 billion to expand US operation - Indian Pharma Post
ENCell and Thermo Fisher Scientific discuss expanded collaboration in cell and gene therapy field - koreabiomed.com
Competent Cells Market Detailed in New Research Report By 2032 | - openPR.com
Thermo Fisher Scientific Announces $2B Investment to Expand U.S. Operations - Thomasnet
Finanzdaten der Thermo Fisher Scientific Inc-Aktie (TMO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.90%
0.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):